Literature DB >> 4469493

Daunorubicin-DNA: further clinical trials in acute non-lymphoblastic leukemia.

G Cornu, J L Michaux, G Sokal, A Trouet.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4469493     DOI: 10.1016/0014-2964(74)90106-6

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0014-2964            Impact factor:   9.162


× No keyword cloud information.
  9 in total

1.  Comparison of daunorubicin and daunorubicin-DNA complex in the treatment of acute nonlymphoblastic leukemia.

Authors:  C Paul; M Björkholm; I Christenson; L Engstedt; G Gahrton; R Hast; G Holm; A Killander; B Lantz; D Lockner; B Lönnqvist; H Mellstedt; J Palmblad; C Peterson; B Simonsson; A M Stalfelt; A M Udén; B Wadman; G Oberg
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

2.  Comparative studies on the in vitro killing of human normal and leukemic clonogenic cells (CFUc) by daunorubicin, daunorubicinol, and daunorubicin-DNA complex.

Authors:  M Beran; B Andersson; S Eksborg; H Ehrsson
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

3.  Treatment of acute nonlymphoblastic leukemia in adults with daunorubicin-DNA complex: a preliminary report.

Authors:  G Gahrton; M Björkholm; G Brenning; I Christenson; L Engstedt; S Franzén; B Gullbring; G Holm; C Högman; P Hörnsten; S Jameson; A Killander; C Simonsson-Lindemalm; D Lockner; B Lönnqvist; H Mellstedt; J Palmblad; C Paul; C Pauli; C Peterson; P Reizenstein; B Simonsson; K O Skårberg; A M Udén; B Wadman
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

4.  Uptake and distribution of daunorubicin and daunorubicin-DNA complex in mice as studied by whole-body autoradiography and liquid chromatography.

Authors:  B Andersson; M Beran; B Eberhardsson; S Eksborg; P Slanina
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

5.  Adsorption of fluorescein dyes on albumin microspheres.

Authors:  K Egbaria; M Friedman
Journal:  Pharm Res       Date:  1992-05       Impact factor: 4.200

Review 6.  Carbon dots for cancer nanomedicine: a bright future.

Authors:  Samer Bayda; Emanuele Amadio; Simone Cailotto; Yahima Frión-Herrera; Alvise Perosa; Flavio Rizzolio
Journal:  Nanoscale Adv       Date:  2021-07-08

7.  Human pharmacokinetics of the daunorubicin-DNA complex. An alternative view of the lysosomotropic theory.

Authors:  R Hulhoven; G Sokal; C Harvengt
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

8.  Daunorubicin-DNA and doxorubicin-DNA. A review of experimental and clinical data.

Authors:  A Trouet; D Deprez-De Campeneere
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

9.  Clinical trials with daunorubicin-DNA and adriamycin-DNA in acute lymphoblastic leukemia of childhood, acute nonlymphoblastic leukemia, and bronchogenic carcinoma.

Authors:  A Ferrant; R Hulhoven; A Bosly; G Cornu; J L Michaux; G Sokal
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.